About Wockhardt
Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. Its operations include the production and sale of pharmaceutical and biopharmaceutical formulations, Active Pharmaceutical Ingredients (APIs), and vaccines. It has 12 manufacturing facilities and 3 research centers.
Wockhardt is a multinational biotechnology and pharmaceutical company that offers high-quality, reasonably priced medications to promote global health. It is the top research-based worldwide healthcare company in India, having a strong presence in the biotechnology and pharmaceutical industries as well as a network of cutting-edge super specialty hospitals.
Wockhardt is based in Mumbai, India, and operates fully in the USA, UK, Ireland, and France. Additionally, it is present in emerging markets such as those in Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon, Kuwait, Brazil, Mexico, Vietnam, and the Philippines.
The main focus of Wockhardt is innovation. It makes use of science and technology to create medications and other goods that enhance millions of people’s lives by promoting better health.
Wockhardt wants to see the globe become healthier. Its strategy goal of “More & More with Less & Less” has evolved into novel perspectives, a fresh path toward expansion, patient-centered medical advancements, and ongoing value for all stakeholders.
New Wockhardt.
New way of thinking.
Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt. At Wockhardt, we are looking at new ways of thinking, new ways of working and new ways to touch people’s lives.
Spearheading Research & Development
Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health.
Wockhardt has proved its technical excellence by developing patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D programme with more than 607 scientists, including over 80 doctorates, in the areas of:
Growing presence around the world
Headquatered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.
Intellectual Property
Wockhardt is in the forefront of Intellectual Property creation with 1,733 patents filed till date, of which 228 patents have been granted. Our capability and commitment in pursuing Intellectual Property has been recognised by the Government of India for four years in a row, with an award for the maximum number of ‘Patent filings and Grants from India’. Wockhardt is determined to create benchmarks for a promising future.
Making strides through multi-technological advances
Wockhardt has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations as well as Active Pharmaceutical Ingredients (API).
The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 12 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe.
The state-of-the-art biotech plant in Aurangabad has six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. The Wockhardt Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology.
Creating value through collaborations
Wockhardt works with partners to in-license products in India and out-license products into other regions by capitalising on these collaborative strengths to capture and penetrate new markets.
According to Wockhardt’s MD, Dr. Murtaza Khorakiwala, strategic partnerships are a less capital-intensive way of moving into new territories or acquiring new capabilities. By finding partners with complementary skills, Wockhardt endeavours to find smarter ways to grow and in turn create significant value for all its stakeholders.
Corporate Social Responsibility – Sustainability beyond Profits
Wockhardt works with partners to in-license products in India and out-license products into other regions by capitalising on these collaborative strengths to capture and penetrate new markets.
According to Wockhardt’s MD, Dr. Murtaza Khorakiwala, strategic partnerships are a less capital-intensive way of moving into new territories or acquiring new capabilities. By finding partners with complementary skills, Wockhardt endeavours to find smarter ways to grow and in turn create significant value for all its stakeholders.
Determined to Succeed
Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.
Wockhardt in Diabetes
Wockhardt is a fully integrated, innovation-led company committed to provide high quality biological products at an affordable price for needy patients and healthcare systems across the globe. Wockhardt holds 45 patents in biosimilar and bio better development phase.
Diabetic segment is one of the prime focus area and the product range includes rapid acting, fast-acting and long-acting insulin formulations to meet the needs of patients with different types of diabetes. Insulin and Insulin Analogue products are available in vials and cartridges, making it convenient for patients to use. The company also offers an in-house developed insulin pen, which is an easy-to-use device for administering insulin. Wockhardt holds 16 patents for its insulin pen globally and the patent is valid till 2035.
Wockhardt has a state-of-the-art research and development facility located in Aurangabad, India, where the biosimilar and bio better products are being developed. The facility is equipped with advanced technologies and has a team of highly skilled multidisciplinary scientists who are involved in developing high-quality biological products. The research team has proven expertise in developing products using yeast, E. coli and mammalian cell based expression platforms.
Wockhardt is also equipped with in-house animal facility and glucose clamp facility to conduct preclinical and PK/PD clinical studies for biological products respectively.
Wockhardt has packaging and device development team who are focused on developing innovative packaging and drug delivery devices (Insulin pens) for biosimilar and bio better products. Wockhardt has developed in-house disposable and re-usable insulin pens with patented design.
Wockhardt’s state-of-the-art biotech facilities in Aurangabad, India, have six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. Wockhardt Biotech Park was inaugurated and dedicated to the nation by Honourable President of Indian Republic, Dr. A.P.J. Abdul Kalam in the year 2004 and Wockhardt’s Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology.
Wockhardt’s biological diabetic business has been growing rapidly over the years and Wockhardt’s diabetic biological products are being marketed in 30+ countries around the world. Wockhardt has been expanding its diabetic portfolio by developing new products and entering into partnerships with other companies.
In conclusion, Wockhardt’s biological business has been a key growth driver for the company in recent years. The company’s focus on research and development, state-of-the-art manufacturing facilities, and global presence has enabled it to become a leading player in the biosimilar market. With the increasing demand for diabetic biosimilar and bio better products, Wockhardt is well-positioned to continue its growth trajectory in the coming years.
For more information log on to
www.wockhardt.com
Have Medical Queries?
Kindly drop your questions here –
wockmed@wockhardt.com